Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis
Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis
复制标题
DOI：
10.1182/blood-2009-11-252601
复制
发表时间：
2010-07-29
期刊：
影响因子：
20.3
通讯作者：
Taniguchi, Shuichi
中科院分区：
文献类型：
--
作者：
Takagi, Shinsuke;Ota, Yasunori;Taniguchi, Shuichi
虽然异基因造血干细胞移植最近已被应用于骨髓纤维化患者的可重复的植入和骨髓纤维化的决议，没有数据描述脐带血移植的结果。我们描述了14例原发性（n = 1）和继发性骨髓纤维化（n = 13）谁接受了降低强度脐带血移植。预处理方案包括氟达拉滨和移植物抗宿主病预防，包括单独使用环孢菌素/他克莫司（n = 6）或他克莫司和麦考酚酸酯联合使用（n = 8）。13例患者在中位23天内实现中性粒细胞植入。中性粒细胞和血小板植入的累积发生率在第60天和第100天分别为92.9%和42.9%。移植后嵌合体分析显示，所有患者在中位14天内均为完全供体类型。从供体细胞移植的角度来看，即使对于严重骨髓纤维化的患者，使用脐带血也是可行的。（血。2010; 116（4）：649-652）
Although allogeneic hematopoietic stem cell transplantation has recently been applied to patients with myelofibrosis with reproducible engraftment and resolution of marrow fibrosis, no data describe the outcomes of umbilical cord blood transplantation. We describe 14 patients with primary (n = 1) and secondary myelofibrosis (n = 13) who underwent reduced-intensity umbilical cord blood transplantation. Conditioning regimens included fludarabine and graft-versus-host disease prophylaxis composed cyclosporine/tacrolimus alone (n = 6) or a combination of tacrolimus and mycophenolate mofetil (n = 8). Thirteen patients achieved neutrophil engraftment at a median of 23 days. The cumulative incidence of neutrophil and platelet engraftment was 92.9% at day 60 and 42.9% at day 100, respectively. Posttransplantation chimerism analysis showed full donor type in all patients at a median of 14 days. The use of umbilical cord blood could be feasible even for patients with severe marrow fibrosis, from the viewpoint of donor cell engraftment. (Blood. 2010; 116(4): 649-652)